Skip to main content
Top
Published in: Supportive Care in Cancer 12/2021

01-12-2021 | Fertility | Original Article

Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience

Authors: Jane E. Rogers, Terri L. Woodard, Arvind Dasari, Bryan Kee, Prajnan Das, Brian K. Bednarski, John M. Skibber, Miguel A. Rodriguez-Bigas, Cathy Eng

Published in: Supportive Care in Cancer | Issue 12/2021

Login to get access

Abstract

Purpose

Colorectal cancer (CRC) is a malignancy that usually occurs in older age individuals. However, CRC cases in young adults are on the rise, and this increase is expected to continue. Young adult CRC requires the healthcare team to familiarize themselves with the unique needs of this population, including concerns about treatment-related infertility. We performed a retrospective review to determine how often our patients, 18–39 years old (yo), had discussions regarding fertility preservation prior to starting stage III CRC treatment.

Methods

Our electronic health record was utilized to identify adult patients < 40 yo with a stage III CRC diagnosis during 1/1/2015–9/1/2019. Fertility preservation discussions were determined by searching the patient’s EHR chart. Progress notes from the medical oncology, surgery, and/or radiation oncology teams were reviewed. Additionally, notes from our fertility specialist’s team were reviewed when consulted.

Results

One hundred and three patients met criteria. Patients were 21–39 yo at diagnosis (median age of 34 yo). Fifty-two percent were male while the remaining 48% were female. Forty-six percent had stage III colon cancer while 54% had stage III rectal cancer. Search terms and progress notes were utilized to determine if discussions were documented. Fertility discussions were documented in 73% of cases while 27% of patients lacked documentation regarding fertility.

Conclusion

Our results show that most of our young adult stage III CRC population participate in fertility preservation discussions. However, in order to capture all patients, we recognize that a more formal approach is warranted. We additionally recommend these discussions occur with all patients of child-bearing age.
Literature
2.
go back to reference Close AG et al (2019) Adolescent and young adult oncology-past, present, and future. CA Cancer J Clin 69(6):485–496CrossRef Close AG et al (2019) Adolescent and young adult oncology-past, present, and future. CA Cancer J Clin 69(6):485–496CrossRef
3.
go back to reference Barr RD et al (2016) Cancer in adolescents and young adults a narrative review of the current status and a view of the future. JAMA Pediatr 170(5):495–501CrossRef Barr RD et al (2016) Cancer in adolescents and young adults a narrative review of the current status and a view of the future. JAMA Pediatr 170(5):495–501CrossRef
4.
go back to reference Barnett M et al (2016) Psychosocial outcomes and interventions among cancer survivors diagnosed during adolescence and young adulthood (AYA): a systematic review. J Cancer Surviv 10(5):814–831CrossRef Barnett M et al (2016) Psychosocial outcomes and interventions among cancer survivors diagnosed during adolescence and young adulthood (AYA): a systematic review. J Cancer Surviv 10(5):814–831CrossRef
7.
go back to reference Bailey CE et al (2015) Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg 150(1):17–22CrossRef Bailey CE et al (2015) Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg 150(1):17–22CrossRef
10.
go back to reference Ben-Aharon I et al (2015) The impact of oxaliplatin on the gonads: from bench to bedside. J Clin Oncol 33(3) Ben-Aharon I et al (2015) The impact of oxaliplatin on the gonads: from bench to bedside. J Clin Oncol 33(3)
12.
go back to reference Oktay K et al (2018) Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 36(19): 1994-+ Oktay K et al (2018) Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 36(19): 1994-+
13.
go back to reference Kumar A et al (2012) Fertility risk discussions in young patients diagnosed with colorectal cancer. Curr Oncol 19(3):155–159CrossRef Kumar A et al (2012) Fertility risk discussions in young patients diagnosed with colorectal cancer. Curr Oncol 19(3):155–159CrossRef
14.
go back to reference Strong M, Peche W, Scaife C (2007) Incidence of fertility counseling of women of child-bearing age before treatment for colorectal cancer. Am J Surg 194(6):765–768CrossRef Strong M, Peche W, Scaife C (2007) Incidence of fertility counseling of women of child-bearing age before treatment for colorectal cancer. Am J Surg 194(6):765–768CrossRef
15.
go back to reference Lewin J, Ma JMZ, Mitchell L et al (2017) The positive effect of a dedicated adolescent and young adult fertility program on the rates of documentation of therapy-associated infertility risk and fertility preservation options. Support Care Cancer. 25(6):1915–1922CrossRef Lewin J, Ma JMZ, Mitchell L et al (2017) The positive effect of a dedicated adolescent and young adult fertility program on the rates of documentation of therapy-associated infertility risk and fertility preservation options. Support Care Cancer. 25(6):1915–1922CrossRef
Metadata
Title
Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience
Authors
Jane E. Rogers
Terri L. Woodard
Arvind Dasari
Bryan Kee
Prajnan Das
Brian K. Bednarski
John M. Skibber
Miguel A. Rodriguez-Bigas
Cathy Eng
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-021-06309-3

Other articles of this Issue 12/2021

Supportive Care in Cancer 12/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine